Loading
A Chinese study of about 5,000 people building a blood test that combines DNA methylation and fragment patterns for 13 cancers.
INSPIRE (NCT06440018) is an observational study sponsored by Singlera Genomics Inc with Fudan University, Hubei Cancer Hospital, China-Japan Friendship Hospital and others. It develops and validates in a blinded set a machine-learning multi-cancer early detection model integrating circulating DNA methylation and fragmentomics.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 21 February 2025), with an estimated 5,350 participants, a start on 20 July 2024 and primary completion expected on 28 February 2025.
Shares Singlera Genomics, PanSeer, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Singlera Genomics, PanSeer, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/